Back to results
US 8,273,351 B2Granted
Fc receptor binding proteins
AssigneesDyax Corp., Syntonix Pharmaceuticals, Inc.
InventorsChristopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato
Life of this patent
Estimating the term…
Abstract
This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
Claims6
An isolated antibody comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the antibody binds to human FcRn;
- and wherein
- the HC comprises:
- a HC CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO:144) or VYAMG (SEQ ID NO:156),
- a HC CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO:145) or SIGSSGGPTKYADSVKG (SEQ ID NO:157), and
- a HC CDR3 comprising the amino acid sequence LSTGELY (SEQ ID NO:146), LSIRELV (SEQ ID NO:158), LSIVDSY (SEQ ID NO:164), LSLGDSY (SEQ ID NO:170), or, LAIGDSY (SEQ ID NO:176);
- and
- the LC comprises:
- a LC CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO:141),
- a LC CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO:142), and
- a LC CDR3 comprising the amino acid sequence CSYAGSGIYV (SEQ ID NO:143).
7 more elements
Dependencies are inferred from the claim text.